Full Press Release Details
Pharma Regains Nasdaq Listing Compliance
WALTHAM, Mass., Sept.
23, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"),
a clinical-stage company focused on developing products for treating disorders of the eye, announced today that the Company has
regained compliance with Nasdaq Listing Rule 5550 (a)(2), which concerns minimum bid price listing requirements.
to be in full compliance with this listing standard and that the matter has been deemed closed by Nasdaq", said Stephen From,
EyeGate's Chief Executive Officer.
EyeGate is a clinical-stage
specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the
EyeGate's lead product,
Ocular Bandage Gel ("OBG"), is based on a modified form of the natural polymer hyaluronic acid, which is a gel that
possesses unique properties providing hydration and healing when applied to the ocular surface. EyeGate is in the clinic for two
different patient populations: photorefractive keratectomy ("PRK") surgery to demonstrate corneal wound repair and
punctate epitheliopathies ("PE"), which includes dry eye.
The objective of OBG is
to re-epithelialize the cornea, reduce the risk of infection, improve symptoms, and improve ocular surface integrity. Often current
treatments fall short as they are ineffective in protecting and enabling corneal re-epithelialization.
If EyeGate achieves successful
completion of the PRK pivotal study and subsequent FDA approval, EyeGate believes OBG will be the only prescription hyaluronic
acid eye drop in the U.S. and the only eye drop in the U.S. approved for the healing of corneal epithelial defects. Additionally,
if the clinical trial for patients with PE is successful, EyeGate believes OBG will be the only eye drop in the U.S. approved for
the treatment of PE.
other product, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the
ocular tissues through EyeGate's proprietary innovative drug delivery system, the EyeGate II Delivery System.
For more information,
please visit www.EyeGatePharma.com.
EyeGate Social Media
EyeGate uses its website
(www.EyeGatePharma.com), Facebook page (https://www.facebook.com/ EyeGatePharma/), corporate Twitter account (https://twitter.com/EyeGatePharma),
and LinkedIn page (https://www.linkedin.com/company/135892/) as channels of distribution of information about EyeGate and its product
candidates. Such information may be deemed material information, and EyeGate may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should monitor EyeGate's website and its social media accounts in addition
to following its press releases, SEC filings, public conference calls, and webcasts. The social media channels that EyeGate intends
to use as a means of disclosing the information described above may be updated from time to time as listed on EyeGate's investor
Forward-Looking Statements
Some of the statements
in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities
Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things,
the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate's products, including
EyeGate's OBG product, its EGP-437 Combination Product, as well as the success thereof, with such approvals or success may
not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results
to differ materially from the statements set forth in this press release, including, among other things, certain risk factors described
under the heading "Risk Factors" contained in EyeGate's Annual Report on Form 10-K filed with the SEC on March
1, 2019 or described in EyeGate's other public filings. EyeGate's results may also be affected by factors of which
EyeGate is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release.
EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect
any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such
Edison Advisors for EyeGate Pharmaceuticals